|
Market Cap (17-May) $1,668,273,536 (454th) |
Close (30-Jun) $12.25 |
Volume (30-Jun) 261,029 |
Shortsold (5-May) 7,255,072 (5.76%) (39th) |
|
52w High $24.00 |
52w Low $8.61 |
P/E 76.34 |
EPS 1.09 |
NEU released this announcement to the ASX on 18 April 2023, 9:50. The announcement is marked as price sensitive, and is 7 page(s) in length and 330.95kb in size.
You can view all announcements from NEU and see how they appear on a price chart on the announcements page.
At the date of this announcement, NEU was 0.675% short sold according to ASIC data. It was ranked the 280th most shorted stock on the ASX. It is now ranked as the 39th most shorted stock on the ASX with 5.756% of total shares short sold as of the latest reported data (05 May 2025).
| Other Recent Announcements from NEU | |
|---|---|
| Neuren completes enrolment in Phelan-McDermid Phase 2 trial | 30 June 2023, 9:36 |
| Neuren opens first site in US for Prader-Willi Phase 2 trial | 28 June 2023, 9:55 |
| Change of Director's Interest Notice | 14 June 2023, 18:44 |
| DAYBUE (trofinetide) launched in US - Neuren earns US$40m | 18 April 2023, 9:50 |
| Application for quotation of securities - NEU | 27 March 2023, 13:27 |
| Investor Presentation, 14 March 2023 | 14 March 2023, 8:34 |
| Notification of investor webinar | 13 March 2023, 14:30 |
You must be logged in to post a reply.
Neuren Pharmaceuticals 